A Phase 2 Randomized, Double-blind Trial Evaluating the Effects of Chloroquine in Breast Cancer

Breast Cancer Clinical Trial

— CUBiC  

Official title:

A Phase 2 Randomized, Double-blind, Window of Opportunity Trial Evaluating Clinical and Correlative Effects of Chloroquine as a Novel Therapeutic Strategy in Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02333890
• Other study ID #: OTT 14-02
• Status: Recruiting
• Phase: Phase 2
• First received: January 5, 2015
• Last updated: November 17, 2016
• Start date: July 2015
• Est. completion date: March 2018

Study information

• Verified date: November 2016
• Source: Ottawa Hospital Research Institute
• Contact: Angel Arnaout, MD
• Phone: 613-798-5555
• Email: anarnaout[@]toh.on.ca
• Is FDA regulated: No
• Health authority: Canada: Health CanadaCanada: Ethics Review Committee
• Study type: Interventional

Clinical Trial Summary

Chloroquine (CQ) is a well known, well tolerated medication that has been used for many years traditionally for arthritis, lupus, and malaria. It has anti-inflammatory properties but is often the drug of choice for arthritis and malaria due to its few side effects. Recently, laboratory investigations have proven that CQ may potentially have anti-cancer properties, by inhibiting a process which allows cancers such as breast cancer to continue to grow (a process known as "autophagy"). Therefore, this study will look at how well CQ can inhibit the growth of breast cancers in patients while waiting for surgery.

Description:

Patients diagnosed with breast cancer can sometimes wait up to 6 weeks for their surgery. The wait leading up to surgery is a potentially long and anxious time. Since no treatment is happening during this period anyway, this study will allow patients to receive CQ during this waiting period. This study will compare CQ treatment before surgery with the standard approach during this time, which is no treatment.

Although CQ is widely used for the treatment of arthritis and malaria, CQ is considered investigational for use in breast cancer.

The study will NOT interfere with the routine assessments as part of the pre-operative care, NOR will it delay the date of surgery.

This study compares the effects of the CQ to placebo. Participants will be randomized 1:1 and be provided with the blinded placebo or QC (500mg daily) during the wait time. Biomarker testing will be performed on the initial biopsy tissue and at the time of surgery as well as blood work. There is also an opportunity for participants to enrol in the optional sample collection for future research.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: March 2018
• Est. primary completion date: March 2017
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• newly diagnosed histologically confirmed primary invasive breast cancer who is currently not undergoing any treatment while awaiting surgery in the next 2-6 weeks

• tumour = 1.5 cm by palpation or imaging

• ECOG performance status 0-2

• written informed consent for the study

Exclusion Criteria:

• Known Metastatic breast cancer

• history of pre-existing known retinal or ocular pathology patient has only one functioning eye

• abnormal hepatic function (serum AST or ALT >3x upper limit of normal)

• currently on CQ or HCQ or has been on the drug within the past 3 months for other conditions

• known history of psoriasis

• known history of epilepsy or seizures

• electrocardiogram showing QT prolongation based on QTc interval >450 ms

• inability to comply with a study protocol (abuse of alcohol, drugs or psychotic states)

• current known pregnancy or actively nursing

• allergic reactions to quinolones or CQ

• inability to consent.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Invasive Breast Cancer

Intervention

Drug:
• Chloroquine
chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
• Placebo

Locations

Country	Name	City	State
Canada	The Ottawa Hospital Woman's Breast Health Centre	Ottawa	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
Ottawa Hospital Research Institute

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Assessment of Toxicity of CQ in Breast Cancer Patients	Even through CQ has an excellent safety profile and the dose of 500 mg/day is well within the dosage in which toxicity is measured, all adverse and serious adverse events while on CQ will be monitored as per the study assessments calendar via the Health Canada Pharmacovigilance program, Ottawa Hospital Science Network-REB and Data Safety Monitoring Board. As the most serious adverse events with CQ use are ocular events, the American Academy of Ophthalmology recommends ophthalmologic screening and management of patients on CQ. Given the limited duration patients will be taking CQ, it is not expected that any ocular events will be observed, however, for enhanced safety, we have 3 ophthalmology collaborators and we will mandate intense vigilance with an ophthalmologic screening exam at baseline, at one month post surgery, and a final at 4-6 months after stopping CQ.	baseline and at 2-6 weeks, the day of surgery	No
Other	Differential Gene and Expression using Microarray Analysis.	The breast cancer tissue collected and stored during this clinical trial will offer a unique opportunity to study the effect of CQ on the biology of human breast tissue. RNA and gene expression levels will be extracted from participant samples that have been treated with CQ. Potential differentially expressed targets will be confirmed by quantitative RT-PCR using specific primers and normalization to endogenous ß-actin or GAPDH as controls.	baseline and at 2-6 weeks, the day of surgery	No
Primary	Effect of a brief course of CQ on tumour proliferation and apoptosis	We will assess relative changes in proliferative and apoptotic response indices based on Ki67 and TUNEL assays in primary breast cancer biopsies pre- and post-treatment with CQ, as these changes occur more rapidly than gross changes in tumour volume.	baseline and at 2-6 weeks, the day of surgery	No
Secondary	Measure of Circulating CQ Metabolites	Plasma samples collected at baseline and at surgery will be assessed for levels of CQ and its metabolite desethylchloroquine (DECQ) by high-performance liquid chromatography (HPLC) as described	baseline and at 2-6 weeks, the day of surgery	No
Secondary	Autophagic Markers in Cancerous and Stromal Tissue	Immunohistochemical detection of proteins such as Beclin 1, LC3, and p62 which are required for autophagosome formation have been extensively studied in clinical tumour samples, and will be assessed in participant samples pre and post-CQ treatment.	baseline and at 2-6 weeks, the day of surgery	No